These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28758583)

  • 1. New Trends in the Treatment of Schizophrenia.
    Meltzer HY
    CNS Neurol Disord Drug Targets; 2017; 16(8):900-906. PubMed ID: 28758583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
    Meltzer HY; Massey BW; Horiguchi M
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.
    Rajagopal L; Kwon S; Huang M; Michael E; Bhat L; Cantillon M; Meltzer HY
    Behav Brain Res; 2017 Aug; 332():180-199. PubMed ID: 28373127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
    Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
    J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine Dâ‚‚ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
    Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
    Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics as a tool in the therapy of schizophrenia.
    Wilffert B; Zaal R; Brouwers JR
    Pharm World Sci; 2005 Feb; 27(1):20-30. PubMed ID: 15861931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.
    Schreiber R; Newman-Tancredi A
    Neurobiol Learn Mem; 2014 Apr; 110():72-80. PubMed ID: 24423786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurochemical arguments for the use of dopamine D
    Huang M; Kwon S; He W; Meltzer HY
    Pharmacol Biochem Behav; 2017 Jun; 157():16-23. PubMed ID: 28455126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT
    Huang M; Kwon S; Rajagopal L; He W; Meltzer HY
    Psychopharmacology (Berl); 2018 Oct; 235(10):2795-2808. PubMed ID: 30066135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.